drugset

drugset / Trial / NCT06018506

A Phase I Study of BR108 in Hematological Malignancies

NCT06018506 ↗

Phase 1 Terminated 8 enrolled BioRay Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

A Phase I study of BR108 in hematological malignancies

Timeline

Start: 2023-03-18
Primary completion: 2024-05-27
Completion: 2024-06-21

Outcome

Outcome not reported

Stopped (Business): “Adjustment of Company R\&D strategy”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BR108	Unknown	—	Intravenous

Indications